About EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ)
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales0.14
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions
What is EPIRUS Biopharmaceuticals' stock symbol?
EPIRUS Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."
How were EPIRUS Biopharmaceuticals' earnings last quarter?
EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) issued its quarterly earnings data on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.07. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $0.41 million. View EPIRUS Biopharmaceuticals' Earnings History.
Who are some of EPIRUS Biopharmaceuticals' key competitors?
Who are EPIRUS Biopharmaceuticals' key executives?
EPIRUS Biopharmaceuticals' management team includes the folowing people:
- Mr. Jeff Kagy, VP of HR & Admin.
- Mr. Robert Ticktin, Sr. VP, Gen. Counsel and Sec. (Age 56)
- Jason Yap, Head of Global Regulatory Affairs and Sr. Director
- Dr. Louis Boon Ph.D., Head of CLG, Bioassay & Process Devel.
- Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
Has EPIRUS Biopharmaceuticals been receiving favorable news coverage?
News coverage about EPRSQ stock has trended somewhat positive on Tuesday, according to Accern. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EPIRUS Biopharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.28 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of EPIRUS Biopharmaceuticals?
Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EPIRUS Biopharmaceuticals' stock price today?
One share of EPRSQ stock can currently be purchased for approximately $0.0030.
How big of a company is EPIRUS Biopharmaceuticals?
EPIRUS Biopharmaceuticals has a market capitalization of $80,000.00 and generates $580,000.00 in revenue each year.
How can I contact EPIRUS Biopharmaceuticals?
EPIRUS Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]
MarketBeat Community Rating for EPIRUS Biopharmaceuticals (EPRSQ)MarketBeat's community ratings are surveys of what our community members think about EPIRUS Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings History and Estimates Chart
EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2016||Q1 2016||($0.53)||($0.66)||$2.00 million||$0.80 million||View||N/A|
|3/15/2016||Q415||($0.56)||($0.63)||$0.41 million||$0.29 million||View||Listen|
|8/7/2015||Q215||($0.38)||($0.65)||$0.40 million||$0.05 million||View||N/A|
|5/12/2015||Q1||($0.43)||($0.39)||$0.68 million||$0.03 million||View||N/A|
|8/11/2014||Q2 2014||($1.20)||($1.52)||$1.50 million||$1.13 million||View||N/A|
|5/9/2014||Q114||$0.20||($0.15)||$9.00 million||$1.60 million||View||N/A|
|3/13/2014||($0.14)||($0.29)||$3.20 million||$3.77 million||View||N/A|
|11/4/2013||Q313||($0.50)||($0.46)||$3.66 million||$3.40 million||View||N/A|
|8/1/2013||Q2 2013||($0.07)||($0.08)||$2.91 million||$3.89 million||View||N/A|
|5/2/2013||Q1 2013||($0.07)||($0.06)||$3.44 million||$3.70 million||View||N/A|
|3/6/2013||Q4 2012||($0.08)||($0.06)||$3.12 million||$3.67 million||View||N/A|
EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.06%
EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/21/2015||Robert Ticktin||General Counsel||Buy||3,000||$3.72||$11,160.00||3,000|| |
|12/17/2015||Aurentz Vincent||Insider||Buy||2,200||$3.43||$7,546.00||2,200|| |
|12/16/2015||Amit Munshi||CEO||Buy||8,270||$2.80||$23,156.00|| |
|12/15/2015||Amit Munshi||CEO||Buy||8,069||$2.87||$23,158.03|| |
|12/9/2015||Amit Munshi||CEO||Buy||13,190||$4.07||$53,683.30|| |
|12/9/2015||Aurentz Vincent||Insider||Buy||2,800||$3.85||$10,780.00|| |
|9/21/2015||Amit Munshi||CEO||Buy||10,000||$6.19||$61,900.00|| |
|9/18/2015||Amit Munshi||CEO||Buy||10,000||$5.99||$59,900.00|| |
|2/6/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||167,316||$5.00||$836,580.00|| |
|2/4/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||52,684||$4.98||$262,366.32|| |
|2/4/2015||Scott M Rocklage||Director||Buy||400,000||$5.00||$2,000,000.00|| |
|1/26/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||38,516||$6.47||$249,198.52|| |
|1/23/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||22,530||$6.29||$141,713.70|| |
EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) News Headlines
No headlines for this company have been tracked by MarketBeat.com
EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) Income Statement, Balance Sheet and Cash Flow Statement
EPIRUS Biopharmaceuticals (OTCMKTS EPRSQ) Stock Chart for Tuesday, April, 24, 2018